American Journal of Cardiology
Volume 105, Issue 2 , Pages 144-148 , 15 January 2010

Relation of Change in Apolipoprotein B/Apolipoprotein A-I Ratio to Coronary Plaque Regression After Pravastatin Treatment in Patients With Coronary Artery Disease

  • Shigemasa Tani, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • Corresponding Author InformationCorresponding author: Tel: (+81) 3-3293-1711; fax: (+81) 3-3295-1859
    • ,
  • Ken Nagao, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Takeo Anazawa, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Hirofumi Kawamata, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Shingo Furuya, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Hiroshi Takahashi, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Kiyoshi Iida

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Michiaki Matsumoto, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Takehiko Washio

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Narimichi Kumabe, MD

      Affiliations

    • Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
    • ,
  • Atsushi Hirayama, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

Received 27 June 2009 ,Revised 25 August 2009 ,Accepted 25 August 2009.

References 

  1. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033
  2. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777–780
  3. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–3009
  4. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259:493–519
  5. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–233
  6. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol. 2001;38:1581–1583
  7. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Treatment—therapeutic lifestyle modification. J Atheroscler Thromb. 2008;15:109–115
  8. Tani S, Nagao K, Anazawa T, Kawamata H, Iida K, Matsumoto M, et al. Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment. Atherosclerosis. 2008;198:360–365
  9. Junyent M, Zambón D, Gilabert R, Cofán M, Núñez I, Ros E. Carotid atherosclerosis in familial combined hyperlipidemia associated with the APOB/APOA-I ratio. Atherosclerosis. 2008;197:740–746
  10. Schmidt C, Fagerberg B. ApoB/apoAI ratio is related to femoral artery plaques in 64-year-old women also in cases with low LDL cholesterol. Atherosclerosis. 2008;196:817–822
  11. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508
  12. Rydén L, Standl E, Bartnik M, Van Den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007;28:88–136
  13. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–2945
  14. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;2008:210–247
  15. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk (Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation). Diabetes Care. 2008;31:811–822
  16. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38
  17. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565
  18. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the management of elevated cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008;117:494–502
  19. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation. 2004;110:1061–1068
  20. Ishikawa K, Tani S, Watanabe I, Matsumoto M, Furukawa K, Nomoto K, et al. Effect of pravastatin on coronary plaque volume. Am J Cardiol. 2003;92:975–977
  21. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, et al. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol. 2005;96:1089–1094
  22. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, et al. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol. 2009;104:464–469
  23. Takayama T, Hiro T, Yamagishi M, Daida H, Saito S, Yamaguchi T, et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of Rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ J. 2007;71:271–275
  24. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using paravasation versus atorvastatin (JAPAN-ACS [Japan assessment of paravasation and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54:293–302

 This study was supported in part by a Nihon University Research Grant for Assistants and Young Researchers, Tokyo, Japan, in 2007.

PII: S0002-9149(09)02316-9

doi: 10.1016/j.amjcard.2009.08.670

American Journal of Cardiology
Volume 105, Issue 2 , Pages 144-148 , 15 January 2010

Article Tools

* Image Usage & Resolution